17,261 trials
Follicular Lymphoma
Primary: Number of Participants With Complete Response — 32 participants
Non-Small Cell Lung Cancer · Brain Neoplasms
Primary: Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System…
Diverticulitis
Primary: Global Symptom Score (GSS) at Week 12, Primary Efficacy Population — 7.3; 4.4; 5.9 Scores on a Scale — p=0.3781
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage
Glioma
Primary: Number of Participants With the Indicated Change From Baseline to Study Completion in Systolic Blood Pressure — 21; 12; 11; 12 participants
GERD · Acid Reflux Disease · Heartburn
Primary: Symptom Intensity Rated by Participants Twice Daily Using an Electronic Reflux Symptom Questionnaire Diary
Influenza
Primary: Oseltamivir Carboxylate AUC12 (Area Under the Curve). — 6; 1; 3; 0 participants
Parkinson's Disease · Psychotic Disorders
Primary: Patient Evaluation of Symptoms of Psychosis. — -9.8; -12.9; -9.7; -10.0 Scores on a scale — p=0.5177
Palliative Care · Pain · Cancer
Primary: Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline — 22; 26; 30; 24 Participants — p=0.33
Secondary Hyperparathyroidism · Hemodialysis
Primary: The Percentage of Participants With a >=50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline Compared to the Average iPTH Obtained in the Last 3 Weeks…
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response (SVR) — 39; 58; 58; 69 Participants — p=0.0126
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
Peritoneal Neoplasms · Intestinal Obstruction · Carcinomatosis
Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants
Diabetes Mellitus, Type 2
Primary: Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint — -0.60; -0.80; -1.24; -1.41 percentage of glycosylated hemoglobin — p=0.0109